http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 07 Jul 2026 05:16:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/TG+Therapeutics+%28TGTX%29+PT+Raised+to+%2420+at+BofA+Securities/26737592.html BofA Securities analyst Alec Stranahan raised the price target on TG Therapeutics (NASDAQ: TGTX) to $20.00 (from $17.00) while maintaining a Underperform rating. http://www.streetinsider.com/Analyst+PT+Change/TG+Therapeutics+%28TGTX%29+PT+Raised+to+%2420+at+BofA+Securities/26737592.html Tue, 07 Jul 2026 05:16:21 -0400 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html <p>TG Therapeutics, Inc. (NASDAQ: TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi (ublituximab-xiiy) in adults with treatment-resistant schizophrenia.</p> <p>The open-label, single-arm, multicenter study is designed to enroll approximately 60 participants between the ages of 18 and 60 who continue to experience significant symptoms despite receiving standard antipsychotic treatment. Participants will receive intravenous Briumvi while remaining on background antipsychotic therapy.</p> <p>The primary endpoint is the proportion of participants achieving at least a 20% reduction from baseline in PANSS total score at Week 12, a threshold commonly used to measure clinical response in schizophrenia studies. Secondary endpoints include additional efficacy http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html Mon, 06 Jul 2026 07:31:06 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html <p>TG Therapeutics, Inc. (NASDAQ: TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi (ublituximab-xiiy) in adults with treatment-resistant schizophrenia.</p> <p>The open-label, single-arm, multicenter study is designed to enroll approximately 60 participants between the ages of 18 and 60 who continue to experience significant symptoms despite receiving standard antipsychotic treatment. Participants will receive intravenous Briumvi while remaining on background antipsychotic therapy.</p> <p>The primary endpoint is the proportion of participants achieving at least a 20% reduction from baseline in PANSS total score at Week 12, a threshold commonly used to measure clinical response in schizophrenia studies. Secondary endpoints include additional efficacy http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html Mon, 06 Jul 2026 07:31:06 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html <p>TG Therapeutics, Inc. (NASDAQ: TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi (ublituximab-xiiy) in adults with treatment-resistant schizophrenia.</p> <p>The open-label, single-arm, multicenter study is designed to enroll approximately 60 participants between the ages of 18 and 60 who continue to experience significant symptoms despite receiving standard antipsychotic treatment. Participants will receive intravenous Briumvi while remaining on background antipsychotic therapy.</p> <p>The primary endpoint is the proportion of participants achieving at least a 20% reduction from baseline in PANSS total score at Week 12, a threshold commonly used to measure clinical response in schizophrenia studies. Secondary endpoints include additional efficacy http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html Mon, 06 Jul 2026 07:31:06 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html <p>TG Therapeutics, Inc. (NASDAQ: TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi (ublituximab-xiiy) in adults with treatment-resistant schizophrenia.</p> <p>The open-label, single-arm, multicenter study is designed to enroll approximately 60 participants between the ages of 18 and 60 who continue to experience significant symptoms despite receiving standard antipsychotic treatment. Participants will receive intravenous Briumvi while remaining on background antipsychotic therapy.</p> <p>The primary endpoint is the proportion of participants achieving at least a 20% reduction from baseline in PANSS total score at Week 12, a threshold commonly used to measure clinical response in schizophrenia studies. Secondary endpoints include additional efficacy http://www.streetinsider.com/FDA/TG+Therapeutics+starts+Phase+2+trial+of+Briumvi+for+schizophrenia/26732716.html Mon, 06 Jul 2026 07:31:06 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html <p>NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia.</p> <p>The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of BRIUMVI in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.</p> <p>Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The initiation of this Phase 2 study represents an exciting step in exploring the potential role of B-cell depletion http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Initiation+of+Phase+2+Trial+Evaluating+BRIUMVI+in+Patients+with+Treatment-Resistant+Schizophrenia/26732689.html Mon, 06 Jul 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Press+Releases/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Globe+Newswire/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Globe+Newswire/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Globe+Newswire/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Globe+Newswire/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX http://www.streetinsider.com/Globe+Newswire/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html <p>AUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=W6U7dX7hXUz6R6yzufn6mpancG7h_DtRCnHzNPfotpIu3499Jf2LfOY2dTyqUU2VOtryb8kstywEy8jx910eCuQ2RFgmh-NyFaiMpWICa7aGYyizTV-W0DE9UdG3VC6BxO5heW4ZqpC4KCodchCVZ2Oc7ueXs0LsVWOtpiuE0L8Dnmcc9wrD7LtLFrZW_pyFjlxV-l1L68s2G8u_6WzlTgdTo1pODLE_DVZgDU5W9f-05FSuhd4Oi34eI3UmlntZAqVofJPyE-qdgKn_LW6cH9ANmEdoXDrGaue5NNj_4SaI17h3P7vAkWjd_Sp6-XH8" rel="nofollow" target="_blank"><u>BioMedWire Editorial Coverage</u></a>: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently <a href="https://www.globenewswire.com/Tracker?data=WL6FmvoPkLtyH31ZhCB8umttJkQoAghEJep9xbafDya4L9WBZ-AN6Sn-o4ARI8YActkk7mw6bT1YzwEzJgrcKA==" rel="nofollow" target="_blank"><u>living</u></a> with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions http://www.streetinsider.com/Globe+Newswire/The+Quest+to+Repair+What+Multiple+Sclerosis+Takes+Away/26682613.html Wed, 24 Jun 2026 08:30:00 -0400 BMY BMY MRK MRK NVS NVS QNTM TGTX TGTX